Equities analysts forecast that Abeona Therapeutics Inc (NASDAQ:ABEO) will post ($0.23) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Abeona Therapeutics’ earnings, with estimates ranging from ($0.26) to ($0.19). Abeona Therapeutics posted earnings of ($0.13) per share during the same quarter last year, which suggests a negative year over year growth rate of 76.9%. The business is scheduled to issue its next quarterly earnings report on Wednesday, November 21st.
On average, analysts expect that Abeona Therapeutics will report full year earnings of ($0.88) per share for the current fiscal year, with EPS estimates ranging from ($0.97) to ($0.74). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.81) per share, with EPS estimates ranging from ($1.13) to ($0.34). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover Abeona Therapeutics.
Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Friday, August 10th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.06). Abeona Therapeutics had a negative net margin of 881.74% and a negative return on equity of 23.02%. The business had revenue of $0.82 million during the quarter, compared to analysts’ expectations of $1.81 million.
Several research firms have recently commented on ABEO. BidaskClub raised shares of Abeona Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, June 28th. B. Riley began coverage on shares of Abeona Therapeutics in a research note on Wednesday, June 27th. They issued a “buy” rating and a $26.00 price objective for the company. TheStreet lowered shares of Abeona Therapeutics from a “c-” rating to a “d+” rating in a research note on Wednesday, August 29th. ValuEngine lowered shares of Abeona Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 30th. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Abeona Therapeutics in a research note on Thursday, September 13th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. Abeona Therapeutics has a consensus rating of “Buy” and an average price target of $26.80.
A number of institutional investors have recently modified their holdings of ABEO. Fortaleza Asset Management Inc. purchased a new position in Abeona Therapeutics in the second quarter worth approximately $104,000. Parkside Advisors LLC purchased a new position in Abeona Therapeutics in the third quarter worth approximately $160,000. United Services Automobile Association purchased a new position in Abeona Therapeutics in the second quarter worth approximately $162,000. Sabby Management LLC purchased a new position in Abeona Therapeutics in the first quarter worth approximately $187,000. Finally, MetLife Investment Advisors LLC lifted its stake in Abeona Therapeutics by 57.8% in the second quarter. MetLife Investment Advisors LLC now owns 19,333 shares of the biopharmaceutical company’s stock worth $309,000 after acquiring an additional 7,085 shares during the last quarter. Institutional investors own 76.24% of the company’s stock.
Shares of NASDAQ ABEO traded up $0.37 during midday trading on Monday, hitting $10.40. The company’s stock had a trading volume of 629,959 shares, compared to its average volume of 886,407. Abeona Therapeutics has a 1 year low of $9.66 and a 1 year high of $22.00. The firm has a market cap of $613.67 million, a price-to-earnings ratio of -15.76 and a beta of 1.10.
About Abeona Therapeutics
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Read More: What are the Benefits of Index Funds?
Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.